Clene Inc. Warrant (CLNNW)

Clene, a clinical-stage biopharmaceutical company, reported a net loss of $(0.78) per share in Q2 2025, with minimal revenue of $27,000. The company continues advancing its CNM-Au8 therapy for neurodegenerative diseases while managing tight cash resources.

Clene Inc., a clinical-stage biopharmaceutical company, announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings on September 9, 2024.

Crude oil prices declined by 1%, while shares of Soligenix surged 282% after the company announced positive interim results for its HyBryte treatment. Helen of Troy reported soft Q1 earnings and lowered its FY25 guidance, leading to a 30% drop in its stock price.